Abstract: The invention relates to lyospheres comprising gonadotropin, the preparation thereof, as well as pharmaceutical preparations containing the same.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein R', R", R.sup.x1, R.sup.x2, R.sup.y1 -R.sup.y4, R.sup.z1, R.sup.z2, a, b, c, d, e, R.sup.0, R.sup.1 and R.sup.2 are defined as in the specification.

Abstract: The invention provides compounds of general formula (I). The compounds have hemoregulatory activities and can be used to stimulate haematopoiesis and for the prevention and treatment of viral, fungal and bacterial infectious diseases.

Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.

Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.

Abstract: A method and apparatus for photothermal detoxification of toxic organic compounds are provided. The apparatus comprises a means for maintaining the gas stream from the targeted source at a temperature of greater than 200.degree. C., an optional air pollution control device, a radiation source which emits radiation at a wavelength of less than 320 nm and an outlet for releasing the nontoxic reaction products to the atmosphere.

Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.

Abstract: A product containing a) glutamine, L-amino acid of glutamine, N-acetyl-L-glutamine and/or glutamine-containing peptide;b) fatty acid containing 2-12 carbon atoms; andc) IGF-1 is useful for treating patients for atrophy of the gut mucosa.

Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein: R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --;R" and R'" are independently methyl or hydrogen;R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, and R.sup.y4 are independently hydroxy or hydrogen;R.sub.0 is a group of the formula ##STR2## R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, phenyl, p-halo-phenyl, p-nitrophenyl, phenoxy, benzyl, p-halo-benzyl, or p-nitro-benzyl; andR.sub.2 is an acyl side chain as defined herein.

Abstract: Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering a dose of greater than 0.3 mg/kg/week of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, serum levels of high-affinity growth hormone binding protein and IGF-I that are at least 2 standard deviations below normal levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I alone or in combination with an amount of growth hormone that is effective in combination with IGF-I.

Abstract: The described invention relates to an essentially stroma-free hemoglobin composition evidencing properties suitable for use as a universally applicable blood plasma expander and to a method for the preparation thereof. Typical, of these properties are desirable oxygen affinity values, desirable vascular retention time and substantial absence of toxic side effects. The described composition comprises human hemoglobin cross-linked intramolecularly through the beta-chains and polymerized with glutaraldehyde. Intramolecular cross-linking is typically effected with 2-nor-2-formylpyridoxal 5-phosphate or a bis-pyridoxal polyphosphate.

Abstract: A composition for the treatment of osteoporosis and the method of treatment of osteoporosis therewith in mammals is disclosed. The method comprises administering Insulin-Like Growth Factor I (IGF-I) to a mammal in need thereof. Need is determined by bone mineral density levels, whether by single measurement (as compared to the population generally) or by a series of measurements evidencing a loss of bone mineral density, or due to a genetic or familial or other predisposition to bone mineral density loss.

Abstract: A compound of the formula: ##STR1## wherein A is benzyl group which has suitable substituent (s), A.sup.a, B and D are each lower alkyl,C is hydrogen or lower alkyl,or a salt thereof.The compound or its salt of the present invention has excellent parasiticidal activities as parasiticides (anthelmintics) for animals and human bodies.

Abstract: A therapeutic agent for treating wounds having properties and actions different from those of growth factors and proteins inducing growth factors, which have strong therapeutic effect is disclosed. The therapeutic agent for treating wounds according to the present invention comprises monocyte chemotactic and activating factor or a variation thereof having a monocyte-attracting property or a derivative of said monocyte chemotactic and activating factor or said variation thereof.

Abstract: The present invention relates generally to methods for treating injury or degeneration of retinal neurons, and in particular photoreceptors, by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating retinal conditions or diseases in which vision is lost such as retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.

Abstract: The present invention relates generally to methods for treating injury or degeneration of retinal ganglion cells by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating optic nerve injury or degeneration associated with glaucoma.

Abstract: The present invention relates to the treatment of an animal to improve carcass quality and/or food conversion efficiency. The invention includes administering to an animal exogenous synthetic growth hormone at a frequency less than daily. The exogenous synthetic growth hormone is not orally administered and is not in a sustained release form. Animals including entire male, female, or castrated male pigs, bovine animals or sheep can be treated in this manner.

Abstract: Porous plastic electrophoresis sponges having pore sizes range from 10.sup.-9 to 10.sup.-3 meters. The sponges are made from polyethylene, polypropylene, polytetrafluoroethylene, polyvinylidine difluoride, polynitrile or polystyrene. The porous plastic sponges are commercially available and are supplied in a prefabricated form which eliminates the preparative and pouring steps required for conventional gel electrophoresis support media. The porous sponges are available in a range of pore sizes and densities for use in a variety of electrophoresis systems to separate a variety of different materials including proteins, peptides and DNA. The porous electrophoresis sponges are relatively inert and may be used with organic solvents.

Abstract: An electrochemical method for forming a partial monomolecular layer of a predetermined extent of coverage of a thiolate of the formula, XRS.sup.-, wherein R can be a linear or branched chain hydrocarbon or an aromatic or the like and X can be any compatible end group, e.g., OH, COOH, CH.sub.3 or the like, upon a substrate such as gold, which involves applying in an electrochemical system a constant voltage preselected to yield the desired predetermined extent of coverage.

Abstract: A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.